Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05BKS
|
|||
| Former ID |
DNAP001329
|
|||
| Drug Name |
Nimotuzumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42; ICD-10: C71] | Approved | [1], [2], [3] | |
| Company |
YM Biosciences
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7988). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | ClinicalTrials.gov (NCT02293356) Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.